6533b863fe1ef96bd12c77e5

RESEARCH PRODUCT

Pazopanib for treatment of typical solitary fibrous tumours: a multicentre, single-arm, phase 2 trial

José Antonio López-guerreroJosé Antonio López-guerreroAxel Le CesnePaola ColliniJosefina CruzJuan Díaz-martínCristina González-aguileraJoaquín DopazoPablo LunaJean-yves BlayEnrique De ÁLavaEnrique De ÁLavaAntonio Lopez-pousaAndrés RedondoMaria Peña-chiletNadia HindiDavid S. MouraAntonio Fernandez-serraMarie KaranianGiovanni GrignaniSilvia StacchiottiJavier Martin-brotoDaniel BernabeuPaolo G. CasaliAntonio GutierrezNicolas PenelDavid Marcilla

subject

0301 basic medicineMalemedicine.medical_specialtyIndazolesPazopanib03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointHumansProspective StudiesNeoplasm MetastasisProspective cohort studySurvival rateProtein Kinase InhibitorsResponse Evaluation Criteria in Solid TumorsAgedSulfonamidesPerformance statusbusiness.industryMiddle Agedmedicine.diseasePrognosisClinical trialSurvival Rate030104 developmental biologyPyrimidinesOncologyResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisSolitary Fibrous TumorsFemalebusinessProgressive diseasemedicine.drugFollow-Up Studies

description

[Background] Solitary fibrous tumour is an ultra-rare sarcoma, which encompasses different clinicopathological subgroups. The dedifferentiated subgroup shows an aggressive course with resistance to pazopanib, whereas in the malignant subgroup, pazopanib shows higher activity than in previous studies with chemotherapy. We designed a trial to test pazopanib activity in two different cohorts of solitary fibrous tumour: the malignant-dedifferentiated cohort, which was previously published, and the typical cohort, which is presented here.

yearjournalcountryeditionlanguage
2020-03-01
10.1016/s1470-2045(19)30826-5http://hdl.handle.net/10261/236288